arrow
C

Candida Vitale

University of Turin
H指数:23
被引数:2,000

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study

真实世界中慢性淋巴细胞白血病的治疗方案选择决定因素:FIRST-CLL研究

2026-09-300
OAAI
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12

cBTKi治疗后无淋巴细胞增多是一种罕见现象,除主要表达于12号染色体三体性的CD49d阳性CLL外。

2026-04-070
OAAI
Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia

B细胞受体与NOTCH1在调控慢性淋巴细胞白血病代谢重编程中的功能协同作用

Leukemia
IF13.4
2026-03-230
OAAI
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia

评估AID诱导突变在慢性淋巴细胞白血病中对B细胞受体通路抑制剂耐药性的作用

2025-12-100
OA
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

慢性淋巴细胞白血病患者接受伊布替尼治疗的弥漫性大b细胞淋巴瘤的Richter转化: 危险因素和结果

Leukemia
IF13.4
2025-06-250
OAAI
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study

家族性慢性淋巴细胞白血病比散发性形式的预后更差:一项意大利病例对照研究

2025-06-140
OAAI
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience
2025-01-140
OAAI
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

家族性与散发性慢性淋巴细胞白血病的比较:一项意大利多中心病例对照研究

BLOOD
IF23.1
2024-11-050
PRE
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study
2024-02-112
PRE
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023-07-012
OA